试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-25
A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)
编号:NCT04305184登记状态:提前终止企业 / 申办者:Astellas Pharma Global Development, Inc.
药物 / 成分:ASP0598、Placebo
登记的停止原因(原文):Lack of Efficacy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-25
Methadone for Spinal Fusion Surgery.
编号:NCT04764825登记状态:提前终止企业 / 申办者:University of Aarhus
药物 / 成分:Methadone、Morphine
登记的停止原因(原文):Due to extremely slow inclusion rates.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-25
Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study
编号:NCT04768504登记状态:提前终止企业 / 申办者:Khashayar Esfahani
药物 / 成分:Tofacitinib 10 mg
登记的停止原因(原文):sponsor decision, due to low recruitment rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-25
A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI
编号:NCT05604521登记状态:提前终止企业 / 申办者:Sanaria Inc.
药物 / 成分:PfSPZ Vaccine、PfSPZ Challenge (7G8)、Normal Saline
登记的停止原因(原文):The main reason for trial discontinuation was the inability to address the primary objectives of the study following an extended gap between the second and third doses.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-22
TATE Versus TACE in Intermediate Stage HCC
编号:NCT03145558登记状态:提前终止企业 / 申办者:Teclison Ltd.
药物 / 成分:Tirapazamine、Doxorubicin
登记的停止原因(原文):Landscape changed and the study population is no longer suitable for the study treatment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-22
FPA150 in Patients With Advanced Solid Tumors
编号:NCT03514121登记状态:提前终止企业 / 申办者:Five Prime Therapeutics, Inc.
药物 / 成分:FPA150、Pembrolizumab
登记的停止原因(原文):The Sponsor terminated the study for reasons unrelated to safety.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-22
Careseng 1370 for Healthy Volunteers
编号:NCT03974516登记状态:提前终止企业 / 申办者:i Cure Biotech Co., Ltd.
药物 / 成分:Careseng 1370
登记的停止原因(原文):This study was early terminated by the sponsor considering the difficulty of subject recruitment in the pandemic of COVID-19.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-22
Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
编号:NCT04918810登记状态:提前终止企业 / 申办者:Australian and New Zealand Urogenital and Prostate Cancer Trials Group
药物 / 成分:Docetaxel intermittent
登记的停止原因(原文):Recruitment lower than expected. The proportion of patients with mGSTPi undetectable prior to chemo. was significantly higher than anticipated. Decision made to close due to insufficient patient numbers to able to obtain meaningful data collection.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-22
Effect of Flow Rate and PH on Muscle Acidosis
编号:NCT05165277登记状态:提前终止企业 / 申办者:Taipei Medical University Hospital
药物 / 成分:Phosphate Buffer Solution
登记的停止原因(原文):TFDA terminated this study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-22
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)
编号:NCT05810961登记状态:提前终止企业 / 申办者:argenx
药物 / 成分:efgartigimod IV、placebo
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗